Cells Webinar | Epigenetics in Myeloproliferative Neoplasms and Acute Myeloid Leukemia
Welcome from the Chairs
12th Webinar on Cells
Epigenetics in Myeloproliferative Neoplasms and Acute Myeloid Leukemia
Research over recent years has revealed the increasingly intricate landscape of acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Today it is well-appreciated that the heterogeneity of malignant cells in both diseases is triggered by sets of cytogenetic abnormalities and somatic mutations. In addition to this genetic complexity, diversification in the epigenome has also been identified as a key player in both tumors. The multidimensional epigenetic picture integrates several layers of (dys)regulated DNA methylation, histone modification, and microRNA modulation. Indeed, abnormal epigenetic signatures, some of which may be linked to specific somatic mutations, frequently present in AML and MPN can profoundly disrupt the phenotype of hematopoietic cells. Furthermore, epigenetic (dys)regulation has emerged as an intersection of several key hallmarks of cancer such as immunology and metabolism.
Thus, understanding the functional link between genetic and epigenetic heterogeneity in AML and MPN, and what they contribute to the disease is an important area of research that would aid clinical decision-making and enhance drug development.
This webinar features several eminent experts in the field of epigenetic in AML and MPN.
Date: 21 October 2021
Time: 3:00 pm CEST | 9:00am EDT | 9:00pm CST Asia
Webinar ID: 857 2369 6091
Webinar Secretariat: cells.webinar@mdpi.com
Chair
Krukenberg cancer Cancer Center (KKH), University Hospital Halle (Saale), Germany
Dr. Haifa Kathrin Al-Ali has been working as a senior physician at the University Clinic for Internal Medicine IV since August 1st, 2016. Her clinical focus includes the treatment of patients with acute and chronic malignant myeloid diseases [myeloproliferative neoplasias (MPN), myelodysplatic syndrome (MDS), acute myeloid leukemia (AML)]. The scientific focus of her work is the implementation of clinical studies and the investigation of the relevance of genetic and epigenetic changes in malignant myeloid diseases.
Invited Speakers
Michael Cross is a biologist with a Ph.D. in molecular genetics (Birmingham, UK) and a history of research into the molecular control of normal and leukemic hematopoiesis. Building on early interests in mechanisms of gene regulation (Gene Centre, Max Planck Institute, Martinsried, Germany) and on the lineage commitment of hematopoietic stem cells (Paterson Institute for Cancer Research, Manchester, UK), Michael is currently interested in the ways in which niche metabolism affects hematopoietic cell fate in normal and neoplastic marrow. He moved to Leipzig in 1998, where he is currently head of laboratory research in the Department of Hematology and Cell Therapy.
Internal Medicine C, Hematology, Oncology, Stem Cell Transplantation and Palliative Care, University Medicine Greifswald, Germany,
Dana-Farber Cancer Institute & Harvard Medical School, Department of Pediatric Oncology, USA
Dr. Perner is a physician scientist working on leukemia epigenetics and the development and optimization of targeted epigenetic therapies for myeloid malignancies. As a postdoctoral research fellow, he worked in the laboratory of Prof. Scott Armstrong at a Dana-Farber Cancer Institute and Harvard Medical School on pharmacologic inhibition of the Menin-MLL1 protein-protein interaction in Acute Myeloid Leukemia. Since June 2021, Dr. Perner is leading the Junior Research Group "Translational Epigenetics of Myeloid Cancers" at the Department of Internal Medicine C at the University Medical Center in Greifswald, Germany.
Webinar Content
On Thursday, 21 October 2021, MDPI and the Journal Cells organized the 12th webinar on Cells, entitled "Epigenetics in Myeloproliferative Neoplasms and Acute Myeloid Leukemia". Chaired by Dr. Haifa Kathrin Al-Ali from Krukenberg cancer Cancer Center (KKH) and University Hospital Halle (Saale) in Germany, the webinar discussed how understanding the functional link between genetic and epigenetic heterogeneity in acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN) could help in the diagnosis, prognosis, treatment and and enhance drug development in the field.
The first speaker to kick off the webinar was Dr. Michael Cross, from University of Leipzig in Germany who discussed how aza-nucleosides affect myeloid cell fate. After him, Dr. Florian Perner from University Medicine Greifswald in Germany, and Dana-Farber Cancer Institute & Harvard Medical School in USA, followed with his talk focused on targeting aberrant MLL-complexes and chromatin in myeloid malignancies. Finally, the chair Dr. Haifa Kathrin Al-Ali discussed the potentials of epigenetic modulation as an add-on player in both diseases.
A Q&A session moderated by the chair was held at the end of the webinar to answer any questions submitted by live online audience and a to further the connections and discussion between the panelists.
The webinar was offered via Zoom, and registration was required for attendance. The full recording can be found below. To stay updated on upcoming Cells webinars organized by MDPI, be sure to sign up for our newsletter by clicking on “Subscribe” at the top of the page.
Program
|
Speaker/Presentation |
Time in CEST |
|
Chair Dr. Haifa Kathrin Al-Ali Chair Introduction |
3:00 – 3:10 pm |
|
Dr. Michael Cross How aza nucleosides affect myeloid cell fate |
3:10 – 3:40 pm |
|
Dr. Florian Perner Targeting aberrant MLL-complexes and chromatin in myeloid malignancies |
3:40 – 4:10 pm |
|
Dr. Haifa Kathrin Al-Ali Potentials of epigenetic modulation as an add-on player in AML and MPN |
4:10 - 4:30 pm |
|
Q&A Session |
4:30 - 4:50 pm |
|
Closing of Webinar Chair Dr. Haifa Kathrin Al-Ali |
4:50 – 5:00 pm |
Relevant SI
Epigenetics in Myeloproliferative Neoplasms and Acute Myeloid Leukemia
Guest Editor: Dr. Haifa Kathrin Al-Ali
Deadline for manuscript submissions: 15 November 2021
Cellular and Molecular Mechanisms of Cancer Metastasis
Guest Editor: Prof. Dr. Ira-Ida Skvortsova
Deadline for manuscript submissions: 1 February 2022
Heterochromatin and Tumorigenesis
Guest Editor: Dr. Florence Cammas
Deadline for manuscript submissions: 1 February 2022
Closed Special Issue
Pathophysiology and Molecular Targets in Myeloid NeoplasiaGuest Editor: Dr. Florian H. Heidel
Deadline for manuscript submissions: closed (15 November 2020)
Sponsors and Partners
Organizers
